Please ensure Javascript is enabled for purposes of website accessibility

Why Five Prime Therapeutics Stock Is on the Rebound Today

By George Budwell - Nov 8, 2017 at 5:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Five Prime Therapeutics and Bristol-Myers Squibb may have a viable pancreatic cancer drug after all.

What happened

After a whopping 41% drop yesterday, shares of the clinical-stage biotech Five Prime Therapeutics (FPRX) are on the mend today as the result of an upbeat clinical update. Specifically, Five Prime provided an investor update this morning regarding the company's experimental pancreatic cancer drug, cabiralizumab, that's currently being assessed in combination with Bristol-Myers Squibb's (BMY 0.34%) immunotherapy Opdivo (nivolumab) in an early-stage study.

The key takeaway is that the combo produced a "durable clinical benefit" in 16% of the patients (5/31) enrolled in this study so far. Bristol and Five Prime also noted that the therapy has an acceptable safety safety profile when assessed across its broader clinical program for solid tumors, although there were three treatment-related deaths. Five Prime's shares ended the day up 17.7% as a result of this news.

Clicking silver metallic balls in motion, with a red ball on the left.

Image source: Getty Images.

So what

Yesterday, investors hit the panic button on Five Prime's stock largely because of these forthcoming results. The problem is that pancreatic cancer rarely responds to experimental therapies in general, and investors seemed to be anticipating that this combo would be yet another dead end.

However, a 16% durable response rate is actually quite respectable for this particular malignancy, and this result would probably even garner an approval from the U.S. Food and Drug Administration if this was a larger, pivotal-stage trial. Five Prime's investor update today appears to have gotten this point across based on today's double-digit move northward.   

Now what

Perhaps most importantly, Bristol and Five Prime announced in today's presentation that the two companies will advance this combination therapy's clinical program by enrolling an additional 30 patients in this ongoing early-stage trial. While there's no way to know if the therapy will have continued success in this extremely hard-to-treat malignancy, it is a product candidate well worth keeping an eye on going forward. An effective pancreatic cancer therapy, after all, could easily generate several hundred million in sales, if not billions. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Five Prime Therapeutics, Inc. Stock Quote
Five Prime Therapeutics, Inc.
FPRX
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$76.22 (0.34%) $0.26

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
323%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.